Windlas Biotech Limited, one of the leading domestic Contract Development and Manufacturing Organization (CDMO) in India, has recently informed exchanges that the company received Good Manufacturing Practices (GMP) certification for its new state-of-the-art injectable facility. The certification, granted by the Food Safety & Drugs Administration Authority of Uttarakhand following a December 2024 inspection, ensures the company adheres to WHO TRS guidelines.
Hitesh Windlass, Managing Director of Windlas Biotech, commented that this certification marks a significant milestone in the company’s growth. It highlights Windlas’ commitment to quality, innovation, and compliance with global standards. The new facility, designed with cutting-edge technology, is equipped with automated systems and robust quality control measures to produce high-quality, sterile injectable formulations.
With this new GMP-certified facility, Windlas Biotech now has all five manufacturing plants complying with GMP standards. This expansion strengthens its position in the CDMO sector, allowing the company to broaden its therapeutic offerings and improve patient access to essential medicines globally.
